Takeda Pharmaceutical (TAK) Other Non-Current Assets (2017 - 2026)

Takeda Pharmaceutical's Other Non-Current Assets history runs 10 years deep, the most recent figure standing at $491.1 million for Q1 2026.

• On a quarterly basis, Other Non-Current Assets rose 6.6% year-over-year to $491.1 million in Q1 2026; TTM through Mar 2026 was $491.1 million, a 6.6% increase from a year earlier, with the FY2026 full-year figure at $511.6 million, up 10.88% from the prior year.
• Other Non-Current Assets fell to $491.1 million in Q1 2026 per TAK's latest filing, from $505.5 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $710.9 million in Q1 2022 and bottomed at $345.6 million in Q1 2024.
• The 5-year median for Other Non-Current Assets is $478.7 million (2023), against an average of $506.9 million.
• Across the five-year window, Other Non-Current Assets tumbled 32.97% in 2023 and soared 55.3% in 2024, its largest moves.
• Year by year, Other Non-Current Assets stood at $472.6 million in 2022, then declined by 21.7% to $370.1 million in 2023, then jumped by 31.81% to $487.8 million in 2024, then increased by 3.63% to $505.5 million in 2025, then retreated by 2.86% to $491.1 million in 2026.
• Per Business Quant, the three latest TAK Other Non-Current Assets figures stand at $491.1 million (Q1 2026), $505.5 million (Q4 2025), and $478.7 million (Q3 2025).